<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TICLOPIDINE </span><br/>(ti-clo'pi-deen)<br/><span class="topboxtradename">Ticlid<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">antiplatelet agent</span><br/><b>Prototype: </b>Clopidogrel<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Platelet aggregation inhibitor that interferes with platelet membrane functioning and therefore platelet interactions.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Prevents release of platelet constituents and prolongs bleeding time.</p>
<h1><a name="uses">Uses</a></h1>
<p>Reduction of the risk of thrombotic stroke in patients intolerant to aspirin.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Prevention of venous thromboembolic disorders; maintenance of bypass graft patency and of vascular access sites in hemodialysis
         patients; improvement of exercise performance in patients with ischemic heart disease and intermittent claudication; prevention
         of postoperative deep venous thrombosis (DVT).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ticlopidine; hematopoietic disease, pathologic bleeding; severe liver impairment.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic function impairment, renal impairment; patients at risk for bleeding from trauma, surgery, or a bleeding disorder;
         GI bleeding; pregnancy (category B). It is not known if ticlopidine is excreted in breast milk. Safety and effectiveness in
         patients 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Stroke Prevention</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg b.i.d. with food<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or just after eating to minimize GI irritation.</li>
<li>Discontinue anticoagulants or fibrinolytic drugs before ticlopidine administration.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness. <span class="typehead">GI:</span> Nausea, vomiting, abdominal cramps; dyspepsia, flatulence, anorexia; abnormal liver function tests (few cases of hepatotoxicity
      reported). <span class="typehead">Hematologic:</span> Neutropenia (resolves in 13 wk), thrombocytopenia, leukopenia, <span class="speceff-life">agranulocytosis</span> (usually within first 3 mo), and <span class="speceff-life">pancytopenia</span>; hemorrhage (ecchymosis, epistaxis, menorrhagia, GI bleeding), <span class="speceff-life">thrombotic thrombocytopenia purpura</span> (usually within first month). <span class="typehead">Skin:</span> Urticaria, maculopapular rash, erythema nodosum (generally occur within the first 3 mo of therapy, with most occurring within
      the first 36 wk). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Increases <span class="alt">total serum cholesterol</span> by 810% within 4 wk of beginning therapy. <span class="alt">Lipoprotein ratios</span> remain unchanged. Elevates <span class="alt">alkaline phosphatase</span> and <span class="alt">serum transaminases.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">antacids</span> decrease bioavailability of ticlopidine. <span class="classification">anticoagulants</span> increase risk of bleeding. <b>Cimetidine</b> decreases clearance of ticlopidine. <span class="classification">corticosteroids</span> counteract increased bleeding time associated with ticlopidine. May decrease <b>cyclosporine</b> levels (one case report). Increases <b>theophylline</b> half-life by 42%, possibly increasing <b>theophylline</b> serum levels. May increase <b>phenytoin</b> levels. <span class="typehead">Food:</span> Food may increase bioavailability of ticlopidine. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 90% absorbed from GI tract; increased absorption when taken with food. <span class="typehead">Onset:</span> Antiplatelet activity, 2448 h; maximal effect at 35 d. <span class="typehead">Peak:</span> Peak serum levels at 2 h. <span class="typehead">Duration:</span> Bleeding times return to baseline within 410 d.  <span class="typehead">Distribution:</span> 90% bound to plasma proteins. <span class="typehead">Metabolism:</span> Rapidly and extensively metabolized in liver. <span class="typehead">Elimination:</span> Only 1% excreted unchanged; 60% of metabolites excreted in urine, 23% in feces. <span class="typehead">Half-Life:</span> 12.6 h; terminal half-life is 45 d with repeated dosing. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor platelet count and bleeding time periodically. Monitor CBC with differentials q2wk from second week to
            end of third month of therapy and thereafter if S&amp;S of infection develop.
         </li>
<li>Report promptly laboratory values indicative of neutropenia, thrombocytopenia, or agranulocytosis.</li>
<li>Monitor for signs of bleeding (e.g., ecchymosis, epistaxis, hematuria, GI bleeding).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly to physician any of the following: Nausea, diarrhea, rash, sore throat, or other signs of infection, signs
            of bleeding, or signs of cholestasis (e.g., yellow skin or sclera, dark urine or clay-colored stools).
         </li>
<li>Understand risk of GI bleeding; do not take aspirin along with ticlopidine.</li>
<li>Do not take antacids within 2 h of ticlopidine.</li>
<li>Keep appointments for regularly scheduled blood tests.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>